Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner(Karl Landsteiner University of Health Sciences), Sonia Vallet(Universitätsklinikum Krems)
Cited by 13
Related Papers
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
|Proceedings of the National Academy of Sciences|2010|235
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
|Blood|2007|150
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
|European Urology Open Science|2022|14